株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

爪真菌症(爪白癬):パイプライン分析

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 192747
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
爪真菌症(爪白癬):パイプライン分析 Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 67 Pages
概要

爪真菌症は慢性の真菌性感染症の一種で、白癬菌(皮膚糸状菌)が爪に伝染することで発症します。主な徴候・症状には、爪が厚くなって切りにくくなる、爪がもろくボロボロとなる、爪の色があせる、普通に動かした際に指・つま先が痛む、といったことが挙げられます。主な治療法には、抗真菌薬による薬物治療や外科手術などがあります。

当レポートでは、世界各国での爪真菌症(爪白癬)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

爪真菌症(爪白癬)の概要

治療薬の開発

  • 爪真菌症向けパイプライン製品:概要
  • 爪真菌症向けパイプライン製品:比較分析

各企業で開発中の爪真菌症治療薬

大学/研究機関で研究中の爪真菌症治療薬

パイプライン製品の概略

  • 臨床段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

爪真菌症治療薬:開発中の製品の一覧(企業別)

爪真菌症治療薬:研究中の製品の一覧(大学/研究機関別)

爪真菌症治療薬の開発に従事している企業

  • Anacor Pharmaceuticals, Inc.
  • エーザイ
  • Helix BioMedix, Inc.
  • Hexima Limited
  • Meiji Seika ファルマ
  • Moberg Pharma AB
  • NAL Pharmaceuticals Ltd.
  • Nihon Nohyaku Co., Ltd.
  • Novabiotics Limited
  • Nuvo Research Inc.
  • Viamet Pharmaceuticals, Inc.

爪真菌症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • AN-2718
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • E-1224
  • ELS-160
  • HB-1275
  • HXP-124
  • ルリコナゾール
  • ME-1111
  • NAL-3216
  • NP-213
  • terbinafine
  • terbinafine
  • VT-1161

爪真菌症治療薬:パイプライン製品の最新動向

爪真菌症治療薬:開発が休止状態の製品

爪真菌症治療薬:開発が中止された製品

爪真菌症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8994IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 4, 6, 3, 3 and 1 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Onychomycosis (Tinea Unguium) - Overview
  • Onychomycosis (Tinea Unguium) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Onychomycosis (Tinea Unguium) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
    • Almirall SA
    • Arno Therapeutics Inc
    • Blueberry Therapeutics Ltd
    • Dermala Inc
    • Eisai Co Ltd
    • Helix BioMedix Inc
    • Hexima Ltd
    • Meiji Seika Pharma Co Ltd
    • Moberg Pharma AB
    • NAL Pharmaceuticals Ltd
    • Nihon Nohyaku Co Ltd
    • Novabiotics Ltd
    • Novan Inc
    • Viamet Pharmaceuticals Inc
  • Onychomycosis (Tinea Unguium) - Drug Profiles
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BB-0305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BB-2603 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Onychomycosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELS-160 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosravuconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-1275 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HXP-124 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • luliconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ME-1111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAL-3210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-213 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-3058 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-208 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • terbinafine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • terbinafine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VT-1161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Onychomycosis (Tinea Unguium) - Dormant Projects
  • Onychomycosis (Tinea Unguium) - Discontinued Products
  • Onychomycosis (Tinea Unguium) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis
      • Aug 10, 2016: Moberg Pharma Announces Approvals to Start Phase 3 Study For MOB-015 In U.S. And Canada
      • Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
      • Jul 13, 2016: Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting
      • Jul 05, 2016: Moberg Pharma announces submission of applications to start Phase 3 studies for MOB-015
      • May 18, 2016: Moberg Pharma Announces Multiple Patent Approvals for MOB-015
      • Mar 02, 2016: Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis
      • Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015
      • Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit
      • Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
      • Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus)
      • Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology
      • Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis
      • Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis
      • Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Arno Therapeutics Inc, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Dermala Inc, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co Ltd, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix Inc, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co Ltd, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H1 2017
  • Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
  • Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2017
  • Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top